IJMPR 2024, 8(3), 61-80

International Journal of Modern Pharmaceutical Research
www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article
SJIF Impact Factor: 6.669

PLANT-DERIVED NANOPARTICLES AS MOLECULAR BIOMARKERS FOR CANCER DIAGNOSTICS AND THERAPY

Keshamma E.[1], Kamal Kant Patra[2], Amit Pandey[3], Anil Kumar[4], Neha Singh[5], Saurav Ghoshal[6], Tanmay Ghosh[7], Vishal Pathak[8] and Chandan Kumar Raikwar*[9]

[1]Associate Professor, Department of Biochemistry, Maharani's Science College for Women, Maharani Cluster University, Palace Road, Bengaluru, India.
[2]Associate Professor, School of Science, YBN University, Rajaulatu, Power Grid Road, Namkum, Ranchi, Jharkhand, India.
[3]Principal & Associate Professor, Department of Pharmacognosy, Manoj Jain memorial College of Pharmacy Satna, Madhya Pradesh, India.
[4]Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India.
[5]Assistant Professor, Department of Pharmaceutical Chemistry, Axis Institute of Pharmacy, Kanpur, Uttar Pradesh, India.
[6]Associate Professor, Department of Pharmaceutics, Shambhunath Institute of Pharmacy, Jhalwa, Prayagraj, Uttar Pradesh, India.
[7]Assistant Professor, Department of Microbiology, Dinabandhu Andrews College, Baishnabghata, South 24 Parganas, Kolkata, West Bengal, India.
[8]Assistant Professor, Department of Pharmaceutical Sciences, Veerayatan Institute of Pharmacy, Gujarat, India.
[9]Assistant Professor, Department of Pharmacy, Satya Sai College of Pharmaceutical Sciences and Research Jalaun Road Orai, Uttar Pradesh, India.

Article Received on: 05/01/2024
Article Revised on: 25/01/2024
Article Accepted on: 15/02/2024

***Corresponding Author**
Chandan Kumar Raikwar
Assistant Professor, Department of Pharmacy, Satya Sai College of Pharmaceutical Sciences and Research Jalaun Road Orai, Uttar Pradesh, India.

ABSTRACT

Plant-derived nanoparticles have shown promise in cancer diagnostics and therapy. Nanoparticles, including lipid-based ones and nanovesicles, have garnered attention for their potential therapeutic benefits, notably in impeding cancer cell proliferation and inhibiting tumor growth. Moreover, their distinct characteristics, such as targeted drug delivery capabilities, present a promising avenue for cancer diagnosis and treatment. Additionally, the exploration of intelligent nanoparticles for precise and personalized cancer therapy is underway, offering tailored treatment modalities. These particles can target specific cancer cells by leveraging biomarkers like proteins, enzymes, genes, and DNA fragments. Furthermore, the review delves into the utilization of nanoparticles derived from plants as carriers for cancer therapy drugs, shedding light on their pharmacokinetics, stability, and therapeutic effectiveness. Plant-based nanoparticles also boast unique optical qualities suitable for cancer diagnostics. For instance, gold nanoparticles synthesized from plant constituents can be easily modified with imaging agents like fluorescent dyes or quantum dots, enabling optical imaging and targeted drug delivery. These nanoparticles play a vital role in cancer cell detection and visualization, facilitating precise diagnosis. The potential of plant-derived nanoparticles in cancer diagnosis and therapy represents a burgeoning field with profound implications for future cancer treatments. This review article explores how plant-derived nanoparticles (PdNPs) can be utilized as molecular biomarkers for cancer diagnosis and therapy. Plant materials offer unique advantages in developing nanoparticles due to their sustainable and eco-friendly characteristics. PdNPs have shown great potential for targeting and diagnosing cancer cells, as well as delivering therapeutic agents.

KEYWORDS: Pharmaceutical Development, Drug Discovery, Cancer Diagnostics, Nanoparticles.

INTRODUCTION

Cancer remains one of the leading causes of mortality worldwide, with its incidence steadily increasing over the years.[1] Timely and accurate diagnosis, followed by effective therapeutic interventions, is crucial for improving patient outcomes and reducing the global burden of cancer.[2] In this context, molecular biomarkers play a pivotal role in cancer diagnostics and therapy. These biomarkers provide valuable information about the presence, progression, and response to treatment of

various types of cancer.[3] Moreover, advancements in nanotechnology have paved the way for the development of novel biomarkers with enhanced sensitivity and specificity. Among these, plant-derived nanoparticles (NPs) have emerged as promising candidates due to their unique properties and biocompatibility.[4]

Molecular biomarkers are molecular or cellular alterations that are indicative of the presence or progression of a disease, such as cancer. In the context of cancer, biomarkers can include genetic mutations, gene expression profiles, protein levels, and other molecular features characteristic of malignant cells.[5] The identification and characterization of these biomarkers have revolutionized cancer diagnostics and therapy in several ways. Firstly, molecular biomarkers enable early detection of cancer, often before symptoms manifest, allowing for timely intervention and improved prognosis.[6] For example, screening tests for specific biomarkers, such as prostate-specific antigen (PSA) for prostate cancer or CA-125 for ovarian cancer, have become integral parts of routine cancer screening protocols.[7] Secondly, biomarkers facilitate accurate diagnosis and classification of cancer subtypes, guiding treatment decisions and personalized medicine approaches.[8] By analyzing the molecular profile of a tumor, clinicians can determine its genetic makeup, predict its response to certain therapies, and tailor treatment strategies accordingly. This paradigm shift towards precision oncology has significantly improved patient outcomes and minimized the risk of overtreatment or undertreatment.[9] Furthermore, molecular biomarkers play a crucial role in monitoring disease progression and treatment response. Through serial measurements of biomarker levels in blood or tissue samples, clinicians can assess the effectiveness of therapy, identify emerging resistance mechanisms, and adjust treatment regimens as needed.[10] This dynamic approach to cancer management allows for timely intervention and optimization of patient care.[2] Overall, molecular biomarkers serve as indispensable tools in the fight against cancer, facilitating early detection, accurate diagnosis, personalized treatment, and monitoring of disease progression. However, conventional biomarkers often suffer from limitations such as low sensitivity, lack of specificity, and invasive sampling procedures. Thus, there is a growing need for innovative biomarkers with improved performance characteristics, which brings us to the emergence of plant-derived nanoparticles as promising candidates.[11]

Plant-Derived Nanoparticles (NPs) as Promising Biomarkers

Plant-derived nanoparticles represent a burgeoning field of research at the intersection of nanotechnology, biotechnology, and medicine.[12] These nanoparticles are derived from various parts of plants, including leaves, stems, roots, and fruits, and exhibit unique physicochemical properties that make them well-suited for biomedical applications. Unlike synthetic nanoparticles, which may raise concerns regarding biocompatibility and toxicity, plant-derived nanoparticles offer inherent advantages such as biodegradability, low immunogenicity, and eco-friendliness.[3,5] The synthesis of plant-derived nanoparticles typically involves the extraction of bioactive compounds from plant sources followed by the conversion of these compounds into nanoscale particles using green chemistry approaches.[13] Various plant species have been explored for nanoparticle synthesis, including but not limited to, green tea, turmeric, neem, garlic, and aloe vera. Each plant source imparts distinct properties to the resulting nanoparticles, such as antioxidant activity, antimicrobial properties, and tumor-targeting capabilities.[14] In the context of cancer diagnostics and therapy, plant-derived nanoparticles hold immense potential as novel biomarkers due to their ability to selectively target cancer cells, deliver therapeutic agents, and modulate cellular signaling pathways. These nanoparticles can be engineered to carry diagnostic payloads such as fluorescent dyes or contrast agents for imaging purposes, enabling non-invasive visualization of tumors and metastatic lesions.[5] Additionally, plant-derived nanoparticles can serve as drug delivery vehicles, encapsulating chemotherapeutic drugs, nucleic acids, or other therapeutic agents and facilitating their targeted delivery to tumor sites while minimizing systemic toxicity.[15] Moreover, plant-derived nanoparticles exhibit inherent biocompatibility and biodegradability, reducing the risk of adverse effects associated with traditional contrast agents or synthetic nanoparticles.[9] Furthermore, their natural origin and eco-friendly synthesis make them appealing candidates for biomedical applications, aligning with the principles of sustainable healthcare and environmental stewardship.[16] This review explores the transformative potential of plant-derived nanoparticles as novel molecular biomarkers for cancer diagnostics and therapy, highlighting their unique properties, synthesis methods, biomedical applications, and the challenges and opportunities associated with their translation into clinical practice.

Fundamentals of Cancer Diagnostics and Therapy

Cancer is a heterogeneous group of diseases characterized by uncontrolled cell growth and proliferation, often leading to the formation of malignant tumors.[17] There are over 100 different types of cancer, each with unique biological characteristics, clinical manifestations, and treatment considerations.[18] Some of the most common types of cancer include breast cancer, lung cancer, prostate cancer, colorectal cancer, and leukemia. Current diagnostic techniques for cancer can be broadly categorized into screening, imaging, and molecular diagnostics.[2] Screening tests aim to detect cancer at an early stage, often before symptoms develop, thereby improving treatment outcomes and reducing mortality. Examples of screening tests include mammography for breast cancer, colonoscopy for colorectal cancer, and Pap smear for cervical cancer.[19] These tests typically involve the detection of abnormal

cells or biomarkers in bodily fluids or tissues. Imaging techniques play a crucial role in the diagnosis and staging of cancer by visualizing internal structures and detecting abnormalities such as tumors or metastatic lesions.[20,4] Common imaging modalities used in cancer diagnostics include X-ray, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound. These techniques provide detailed anatomical and functional information about the location, size, and extent of tumors, guiding treatment planning and monitoring.[21] Molecular diagnostics involve the analysis of genetic, genomic, proteomic, or metabolic alterations associated with cancer development and progression. These techniques enable personalized medicine approaches by identifying specific biomarkers or molecular targets for targeted therapies. Examples of molecular diagnostic tests include polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), gene expression profiling, and next-generation sequencing (NGS).[22] Molecular diagnostics not only aid in cancer diagnosis and classification but also provide valuable insights into tumor biology, prognosis, and treatment response. An instance of magnetic nanoparticles in cancer treatment includes their use as nanocarriers for both diagnosis and hyperthermia therapy are shown in figure 1.[6]



Figure 1: An instance of magnetic nanoparticles in cancer treatment includes their use as nanocarriers for both diagnosis and hyperthermia therapy.

Challenges in Traditional Cancer Diagnostics

Despite significant advancements in cancer diagnostics, several challenges persist, hindering the timely and accurate detection of cancer and the optimization of treatment strategies.

Sensitivity and Specificity: Many traditional diagnostic tests lack sufficient sensitivity and specificity, leading to false-positive or false-negative results. This can result in unnecessary procedures, overtreatment, or delayed diagnosis, impacting patient outcomes and healthcare costs.[23]

Invasive Procedures: Some diagnostic techniques, such as tissue biopsy or surgical exploration, require invasive procedures that carry inherent risks and discomfort for patients. Moreover, these procedures may not always yield sufficient tissue samples for comprehensive analysis, limiting the accuracy of diagnosis and staging.[24]

Accessibility and Affordability: Access to advanced diagnostic technologies may be limited in certain regions or healthcare settings, particularly in low- and middle-income countries. Cost barriers and infrastructure constraints pose challenges to widespread adoption and equitable access to cancer diagnostics, exacerbating disparities in healthcare delivery and outcomes.[25]

Tumor Heterogeneity: Cancer is a highly heterogeneous disease, characterized by genetic and phenotypic diversity both within and between tumors. Traditional diagnostic tests may fail to capture this heterogeneity, resulting in incomplete characterization of the disease and suboptimal treatment selection.[17]

Resistance and Recurrence: Despite initial response to therapy, cancer cells may develop resistance mechanisms over time, leading to treatment failure and disease recurrence. Traditional diagnostic techniques may not always detect minimal residual disease or emerging resistance mutations, necessitating the development of more sensitive and dynamic monitoring strategies.[8]

Emerging Trends in Cancer Therapy

In recent years, significant progress has been made in the field of cancer therapy, with emerging trends focusing on precision medicine, immunotherapy, targeted therapies, and combination approaches.

Precision Medicine: Precision medicine, also known as personalized medicine, involves tailoring treatment strategies to individual patients based on their unique genetic, molecular, and clinical characteristics.[26] Molecular diagnostics play a central role in precision medicine by identifying actionable biomarkers or therapeutic targets that guide treatment selection and optimization. By matching patients with the most effective therapies, precision medicine aims to improve treatment outcomes while minimizing toxicity and adverse effects.[5,27]

Immunotherapy: Immunotherapy harnesses the power of the immune system to recognize and eliminate cancer cells, offering a promising approach for treating various types of cancer.[18] Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and adoptive cell therapy are some of the immunotherapeutic strategies that have demonstrated remarkable efficacy in certain cancer types.[16] Immunotherapy not only enhances antitumor immune

responses but also induces durable responses and long-term immune memory, leading to sustained remissions and improved survival outcomes.[28]

Targeted Therapies: Targeted therapies are designed to selectively inhibit specific molecular targets or pathways involved in cancer development and progression.[5] These therapies exploit the molecular vulnerabilities of cancer cells while sparing normal tissues, minimizing systemic toxicity and adverse effects. Examples of targeted therapies include tyrosine kinase inhibitors, monoclonal antibodies, hormone therapies, and PARP inhibitors.[20] Targeted therapies have revolutionized the treatment landscape for many cancer types, particularly those with driver mutations or oncogenic pathways that can be therapeutically exploited.[29]

Combination Therapies: Combination therapies involve the simultaneous or sequential administration of multiple treatment modalities to enhance efficacy, overcome resistance, and minimize treatment-related toxicity.[17] Combinations of chemotherapy, targeted therapy, immunotherapy, and radiation therapy have shown synergistic effects in preclinical and clinical studies, offering new treatment options for patients with advanced or refractory cancers.[21] Rational combination strategies based on complementary mechanisms of action and synergy between therapeutic agents are being actively investigated to optimize treatment outcomes and overcome resistance mechanisms.[3] Overall, emerging trends in cancer therapy hold great promise for improving patient outcomes, extending survival, and enhancing quality of life.[30] By integrating advances in diagnostics, therapeutics, and personalized medicine, clinicians can tailor treatment strategies to individual patients, optimize therapeutic efficacy, and minimize treatment-related toxicity.[9] However, challenges such as tumor heterogeneity, resistance mechanisms, and access to innovative therapies remain significant barriers that must be addressed through continued research, collaboration, and innovation in cancer care.[31]

Plant-Derived Nanoparticles

Plant-derived nanoparticles (NPs) are nanoscale particles that are synthesized from various parts of plants, including leaves, stems, roots, seeds, and fruits.[18] These nanoparticles are typically generated through green synthesis methods, which involve the reduction or transformation of plant-derived compounds into nanoscale structures using eco-friendly and sustainable approaches.[7] Plant-derived nanoparticles can vary in size, shape, composition, and surface properties, depending on the plant species, extraction method, and synthesis conditions employed.[32]

1. Plant Extract-Based Nanoparticles: Plant extract-based nanoparticles have shown potential in cancer diagnostics and therapy.[21] Nanovesicles derived from plants (referred to as PDNVs) have surfaced as a compelling nanoplatform for biomedical applications. The utilization of naturally synthesized nanoparticles offers notable advantages, including economic viability, environmental friendliness, and time efficiency in nanoparticle production. Plants have exhibited significant potential in yielding diverse phytomedicines with chemopreventive attributes capable of combating prostate cancer.[12] The inherent versatility and ability to serve multiple functions render plant-based nanoparticle platforms a promising avenue for precise cancer diagnosis and treatment.[3] These biogenic nanoparticles, derived from living organisms such as plants, bacteria, fungi, and algae, possess the unique capability to selectively target cancerous cells.[33] Plant extract-based nanoparticles have garnered significant attention recently for their versatile applications in drug delivery, cosmetics, and pharmaceuticals, offering numerous advantages over conventional synthetic nanoparticles.[9] These nanoparticles can be classified into lipid-based nanoparticles, such as liposomes, and polymer-based nanoparticles.[2] Lipid-based nanoparticles consist of a bilayer of lipids and can incorporate plant extracts for drug delivery, cosmetics, and nutraceuticals.[5] Polymer-based nanoparticles, composed of biodegradable polymers, can also integrate plant extracts and find applications in drug delivery, tissue engineering, and regenerative medicine. Several methods are employed to synthesize plant extract-based nanoparticles, including emulsification and solvent extraction, precipitation, and polymerization methods.[34]

2. Phytochemical-Loaded Nanoparticles: Nanoparticles enriched with phytochemicals denote nanoparticles laden or enveloped with plant-derived bioactive compounds.[4] These microscopic entities hold significant potential across various medical applications, encompassing drug delivery, cancer treatment, and nutraceutical formulations.[2] Phytochemicals showcase a wide array of biological functions, ranging from antioxidative and anti-inflammatory properties to anticancer and antimicrobial effects, rendering them invaluable for therapeutic interventions.[35] Embedding phytochemicals within nanoparticles serves to enhance their bioavailability, stability, and therapeutic efficacy, while simultaneously reducing potential adverse effects and facilitating targeted delivery to specific tissues or cells.[12] Various nanoparticle formulations, including liposomes, polymeric nanoparticles, lipid nanoparticles, and solid lipid nanoparticles, can be harnessed for phytochemical encapsulation, providing versatile platforms for drug delivery and controlled release.[6] Phytochemical-loaded nanoparticles have shown promise in preclinical studies for various medical applications, and ongoing research aims to further explore their potential in clinical settings.[8] Overall, phytochemical-loaded nanoparticles represent an innovative approach in modern medicine, harnessing the therapeutic potential of plant-derived compounds for improved health outcomes.[36]

3. Plant-Derived Polymer Nanoparticles: Plant-derived polymer nanoparticles are nanoparticles composed of biodegradable polymers derived from plant-based sources. These nanoparticles have garnered considerable interest in biomedical research due to their potential applications in drug delivery, tissue engineering, and regenerative medicine.[4,37] Utilizing polymers derived from plants presents numerous advantages, including biocompatibility, biodegradability, and sustainability, rendering them appealing substitutes for synthetic polymers sourced from petrochemicals.[11] Plant-derived polymers, encompassing cellulose, chitosan, alginate, and starch, offer versatile options for fabricating nanoparticles utilizing a variety of techniques, such as nanoprecipitation, emulsion polymerization, and electrospinning.[23] These nanoparticles can be loaded with therapeutic agents, such as drugs, proteins, or nucleic acids, and engineered to achieve controlled release profiles, targeted delivery, and enhanced therapeutic efficacy.[38] Plant-derived polymer nanoparticles have shown promise in preclinical studies for applications in cancer therapy, wound healing, and tissue regeneration. Moreover, their natural origin and biocompatibility make them suitable for biomedical applications, with potential for translation into clinical use.[6,7] Continued research into the synthesis, characterization, and biomedical applications of plant-derived polymer nanoparticles is expected to further advance their utility in various medical fields, contributing to the development of innovative therapeutic strategies and improving patient outcomes.[39]

4. Plant Virus-Based Nanoparticles: Viruses found in plants are infectious agents at the nanoscale that can undergo engineering to showcase foreign peptides or proteins on their surface, rendering them valuable platforms for vaccine development, drug delivery, and imaging applications.[40] Utilizing plant virus-based nanoparticles offers numerous advantages, including a high payload capacity, precise control over surface chemistry, and low immunogenicity.[32] Examples encompass tobacco mosaic virus nanoparticles, cowpea mosaic virus nanoparticles, and potato virus X nanoparticles. These varied types of nanoparticles derived from plants present distinctive benefits and functionalities for biomedical applications, including targeted drug delivery, imaging, diagnostics, and theranostics.[37] Figure 2 illustrates the diverse nanomaterials employed in cancer treatment.[41]



Figure 2: Different types of nanomaterial used in the cancer treatment.

Properties and Advantages of Plant-Derived Nanoparticles over Conventional Biomarkers

Plant-derived nanoparticles possess several distinct properties and advantages that distinguish them from conventional biomarkers and synthetic nanoparticles, making them promising candidates for various biomedical applications.

1. Biocompatibility: Plant-derived nanoparticles are composed of natural plant-based materials, such as phytochemicals, polysaccharides, proteins, and lipids, which are inherently biocompatible and biodegradable. These nanoparticles are well-tolerated by living organisms and exhibit low cytotoxicity, minimizing adverse effects on cells, tissues, and organs.[42]

2. Eco-Friendly Synthesis: Green synthesis methods used to produce plant-derived nanoparticles are environmentally friendly and sustainable, involving the use of renewable plant sources, non-toxic reagents, and energy-efficient processes. These eco-friendly synthesis approaches reduce the environmental impact of nanoparticle production and promote the development of sustainable nanotechnologies.[43]

3. Targeting and Specificity: Plant-derived nanoparticles

can be engineered to selectively target cancer cells or specific tissues by functionalizing their surfaces with targeting ligands, antibodies, or peptides. This targeted approach enhances the specificity of nanoparticle accumulation at the site of interest, minimizing off-target effects and improving therapeutic efficacy.[44]

4. Biodegradability: Plant-derived nanoparticles are biodegradable, meaning they can be metabolized and eliminated from the body over time through natural biological processes. Unlike synthetic nanoparticles, which may accumulate in organs and tissues, plant-derived nanoparticles are metabolized into harmless byproducts, reducing the risk of long-term toxicity and side effects.[45]

5. Diversity and Customization: Plant-derived nanoparticles offer a diverse range of materials, structures, and functionalities that can be tailored to specific biomedical applications. Researchers can customize the composition, size, shape, surface chemistry, and payload of plant-derived nanoparticles to optimize their performance for diagnostics, therapy, imaging, or theranostics.[46]

6. Cost-Effectiveness: Plant-derived nanoparticles can be produced at relatively low cost using readily available plant materials and simple synthesis techniques. Compared to synthetic nanoparticles, which may require expensive equipment and specialized expertise, plant-derived nanoparticles offer a cost-effective alternative for biomedical applications, particularly in resource-limited settings.[47] Overall, the unique properties and advantages of plant-derived nanoparticles make them attractive candidates for various biomedical applications, including cancer diagnostics and therapy. These nanoparticles hold great promise for improving the efficacy, safety, and sustainability of cancer treatment modalities, paving the way for more personalized and environmentally friendly approaches to cancer care. Table 1 provide an overview of different types of nanoparticles, highlighting their respective materials, types, size ranges, main components, and main applications in various fields such as imaging, drug delivery, biosensing, and tissue engineering.[48]

Table 1: Overview of Various Types of Nanoparticles, Including Materials, Types, Size Ranges, Main Components, and Main Applications.

Material	Type	Size	Main Component	Main Applications
Gold nanoparticles	Metallic	1-100 nm	Gold (Au)	Imaging, drug delivery, photothermal therapy[4]
Lipid nanoparticles	Liposomal	50-500 nm	Lipids, cholesterol	Drug delivery, gene therapy, vaccine delivery[5]
Iron oxide nanoparticles	Inorganic	1-100 nm	Iron oxide (Fe3O4, Fe2O3)	Magnetic resonance imaging (MRI), hyperthermia[7]
Polymer nanoparticles	Polymeric	10-200 nm	Polymers (e.g., PLGA, PEG)	Drug delivery, imaging, tissue engineering[21]
Quantum dots	Semiconductor	2-10 nm	Semiconductor nanocrystals (e.g., CdSe)	Imaging, biosensing, photodynamic therapy[34]
Carbon nanotubes	Carbon-based	1-100 nm (diameter)	Carbon (graphene sheets)	Drug delivery, biosensing, tissue engineering[10]
Silica nanoparticles	Inorganic	10-200 nm	Silicon dioxide (SiO2)	Drug delivery, imaging, biosensing[19]
Magnetic nanoparticles	Metallic	5-50 nm	Iron, cobalt, nickel	Magnetic resonance imaging (MRI), hyperthermia[1]
Calcium phosphate nanoparticles	Inorganic	10-100 nm	Calcium phosphate (Ca3(PO4)2)	Drug delivery, bone regeneration[30]
Dendrimers	Polymeric	1-10 nm	Branched polymer molecules	Drug delivery, gene therapy, imaging[41]
Liposomes	Liposomal	50-1000 nm	Phospholipid bilayers	Drug delivery, vaccine delivery, gene therapy
Mesoporous silica nanoparticles	Inorganic	50-200 nm	Silica (SiO2)	Drug delivery, imaging, biosensing[21]

Mechanisms of Synthesis and Modification of Plant-Derived Nanoparticles

The synthesis and modification of plant-derived nanoparticles involve several key steps and mechanisms, which vary depending on the type of nanoparticle and the desired properties for a specific application. Common methods for synthesizing plant-derived nanoparticles include.

1. Phytochemical Extraction: Phytochemical extraction is a fundamental process in the synthesis of plant-derived nanoparticles, involving the isolation and concentration

of bioactive compounds from botanical sources.[49] These bioactive compounds, including polyphenols, flavonoids, alkaloids, terpenoids, and saponins, serve as precursors for nanoparticle synthesis and impart therapeutic properties to the resulting nanoparticles. The extraction process is crucial for obtaining high-quality phytochemicals that can be further processed into nanoparticles with desired characteristics for various biomedical applications. Several methods are commonly employed for phytochemical extraction, each with its advantages and limitations. Solvent extraction is one of the most widely used techniques, where plant materials are macerated or soaked in a solvent to dissolve and extract the desired compounds.[50] Common solvents include ethanol, methanol, acetone, and water, each selectively extracting different classes of phytochemicals based on their polarity and solubility. For example, polar solvents like methanol and ethanol are effective for extracting polyphenols and flavonoids, while non-polar solvents like hexane are suitable for extracting lipophilic compounds such as terpenoids. Another extraction method is steam distillation, which involves passing steam through plant materials to vaporize volatile compounds, followed by condensation to collect the distillate. This method is particularly useful for extracting essential oils rich in volatile terpenoids and aromatic compounds from aromatic plants. Steam distillation is preferred for extracting heat-sensitive compounds that may degrade at higher temperatures, ensuring the preservation of bioactive components in their natural form.[51] Supercritical fluid extraction (SFE) is a modern technique that utilizes supercritical fluids such as carbon dioxide (CO2) as solvents to extract phytochemicals from plant materials. In this method, CO2 is pressurized above its critical point to achieve both liquid and gas-like properties, enhancing its solvent power and extraction efficiency. SFE offers several advantages, including high selectivity, low environmental impact, and solvent-free extraction, making it suitable for producing high-quality phytochemical extracts for nanoparticle synthesis. Ultrasonication is another extraction technique that employs high-frequency sound waves to disrupt plant cell walls and release intracellular phytochemicals into the solvent.[52] Ultrasonic extraction is rapid, efficient, and requires minimal solvent consumption compared to conventional methods, making it suitable for large-scale production of phytochemical extracts. Additionally, ultrasonication can enhance the extraction yield and bioactivity of phytochemicals by promoting mass transfer and increasing solvent penetration into plant tissues.[53]

2. Nanoparticle Formation: Nanoparticle formation is a pivotal stage in the synthesis of plant-derived nanoparticles, wherein phytochemicals extracted from botanical sources are processed to produce nanoscale particles with desired characteristics. This process involves various green synthesis methods that are environmentally friendly and utilize sustainable resources.[54] Common techniques for nanoparticle formation include chemical reduction, microwave-assisted synthesis, ultrasonication, and plant-mediated synthesis. Chemical reduction is a widely employed method for nanoparticle synthesis, involving the reduction of metal ions in the presence of phytochemicals to form nanoparticles.[55] Typically, metal salts such as gold chloride (AuCl3) or silver nitrate (AgNO3) are reduced by phytochemicals acting as reducing agents, resulting in the formation of metal nanoparticles. The reaction conditions, including temperature, pH, and reaction time, play a crucial role in controlling the size, shape, and stability of the nanoparticles produced.[56] Microwave-assisted synthesis is a rapid and efficient technique for nanoparticle formation that utilizes microwave irradiation to accelerate chemical reactions. In this method, metal salts and phytochemicals are mixed in a solvent and subjected to microwave irradiation, leading to the rapid reduction of metal ions and formation of nanoparticles. Microwave heating promotes uniform heating and energy distribution, facilitating the synthesis of nanoparticles with controlled size and morphology in a shorter reaction time compared to conventional methods.[57] Ultrasonication is another green synthesis approach for nanoparticle formation that employs high-frequency sound waves to induce cavitation and promote the reduction of metal ions by phytochemicals. Ultrasonic waves generate microbubbles in the reaction mixture, leading to localized heating and pressure changes that enhance the rate of chemical reactions. Ultrasonication is particularly effective for producing nanoparticles with uniform size distribution and high purity, owing to its ability to promote nucleation and particle growth under mild reaction conditions.[58] Plant-mediated synthesis, also known as biofabrication, involves the use of plant extracts or plant-derived biomolecules as both reducing and stabilizing agents for nanoparticle formation. Phytochemicals present in plant extracts, such as polyphenols and flavonoids, exhibit reducing properties that facilitate the reduction of metal ions to form nanoparticles. Additionally, biomolecules such as proteins and polysaccharides present in plant extracts can act as capping agents, preventing the agglomeration and stabilizing the nanoparticles formed. Plant-mediated synthesis offers several advantages, including biocompatibility, cost-effectiveness, and scalability, making it a promising approach for the sustainable production of plant-derived nanoparticles for various applications.[59]

3. Surface Modification: Surface modification is a crucial aspect of the synthesis of plant-derived nanoparticles, involving the alteration of the nanoparticle surface to enhance its stability, biocompatibility, targeting specificity, and therapeutic efficacy. This process allows researchers to tailor the properties of nanoparticles to meet the requirements of specific biomedical applications. Surface modification techniques include coating with biocompatible polymers,

conjugation with targeting ligands or antibodies, encapsulation of drugs or imaging agents, and surface patterning with biomolecules or nanoparticles. One common surface modification strategy is the coating of nanoparticles with biocompatible polymers, such as polyethylene glycol (PEG) or poly(lactic-co-glycolic acid) (PLGA).[60] Polymer coatings provide steric stabilization, preventing aggregation and opsonization of nanoparticles in biological fluids, thereby prolonging their circulation time and enhancing their biocompatibility. Additionally, polymer coatings can serve as carriers for hydrophobic drugs or imaging agents, enabling their encapsulation within nanoparticles and controlled release at the target site. Conjugation with targeting ligands or antibodies is another surface modification approach used to enhance the specificity of nanoparticles for cancer cells or specific biomarkers.[61] Targeting ligands, such as peptides or small molecules, can be conjugated to the surface of nanoparticles to recognize and bind to receptors overexpressed on the surface of cancer cells. Similarly, antibodies targeting specific antigens present on cancer cells can be attached to nanoparticles, enabling selective targeting and internalization into tumor cells while minimizing off-target effects on healthy tissues. Encapsulation of drugs or imaging agents within nanoparticles is a widely used surface modification strategy for controlled release and targeted delivery.[62] Drugs or imaging agents can be encapsulated within the core of nanoparticles during synthesis or loaded onto the surface of pre-formed nanoparticles using various techniques such as physical adsorption or chemical conjugation. Encapsulation protects drugs or imaging agents from degradation and premature release, allowing for sustained release and improved therapeutic efficacy or imaging contrast at the target site. Surface patterning with biomolecules or nanoparticles is an emerging surface modification technique that enables the functionalization of nanoparticles with specific biological ligands or signaling molecules. Nanoparticle surfaces can be patterned with biomolecules such as DNA, proteins, or carbohydrates using techniques such as self-assembly or chemical immobilization. These biomolecules can impart additional functionalities to nanoparticles, such as cell targeting, signaling modulation, or interaction with biological pathways, for applications in diagnostics, therapy, and tissue engineering.[63]

Role of Plant-Derived Nanoparticles in Cancer Diagnostics

Detection and Identification of Cancer Biomarkers

1. Plant-Derived Nanoparticles for Biomarker Detection: Plant-derived nanoparticles represent a promising avenue for biomarker detection in cancer diagnostics, leveraging their unique properties to offer sensitive and specific detection capabilities.[64] These nanoparticles, derived from natural plant-based materials, possess inherent biocompatibility and minimal toxicity, ensuring compatibility with biological samples and reducing the risk of adverse effects. Their surfaces can be readily modified with biomolecule-specific ligands or antibodies, allowing for precise targeting of cancer biomarkers and enhancing the specificity of detection assays. Moreover, plant-derived nanoparticles exhibit signal amplification properties, enabling the detection of low-abundance biomarkers through various enhancement techniques such as enzyme-linked immunosorbent assays (ELISA) or nanoparticle-based signal amplification.[65] This amplification enhances the sensitivity and detection limits of biomarker assays, facilitating the detection of cancer biomarkers even in complex biological samples. Additionally, these nanoparticles offer multiplexed detection capabilities, allowing simultaneous detection of multiple cancer biomarkers from a single sample, providing comprehensive molecular information about the cancer phenotype. Furthermore, the portability and rapidity of plant-derived nanoparticle-based detection platforms enable point-of-care testing, particularly beneficial in resource-limited settings, facilitating early detection and screening of cancer and improving access to timely diagnosis and treatment. Overall, the biocompatibility, surface modifiability, signal amplification, multiplexing capabilities, and suitability for point-of-care testing make plant-derived nanoparticles promising candidates for advancing biomarker detection in cancer diagnostics, with the potential to enhance early detection, prognosis, and personalized treatment strategies for cancer patients. Continued research and development in this field are expected to further optimize the performance and clinical utility of plant-derived nanoparticles in cancer management.[66]

2. Signal Amplification Strategies: Signal amplification strategies are essential components in enhancing the sensitivity and detection limits of biomarker assays, particularly in cancer diagnostics. These strategies aim to amplify the signals generated from the interaction between biomarkers and detection probes, thereby improving the accuracy and reliability of biomarker detection.[67] Several signal amplification techniques are commonly employed, including enzyme-linked immunosorbent assays (ELISA), nanoparticle-based amplification, and nucleic acid amplification methods. ELISA involves the use of enzyme-conjugated detection antibodies to catalyze the conversion of substrate molecules into detectable signals, amplifying the signal output proportional to the concentration of the biomarker. Nanoparticle-based amplification utilizes nanomaterials such as gold nanoparticles or quantum dots, which can bind to multiple detection probes or target biomolecules, leading to signal enhancement through collective effects such as plasmon resonance or fluorescence resonance energy transfer.[68] Additionally, nucleic acid amplification methods, such as polymerase chain reaction (PCR) or loop-mediated isothermal amplification (LAMP), can be employed to amplify the nucleic acid signals derived from biomarker detection, enabling sensitive and specific detection of cancer-related genetic alterations. These signal amplification

strategies play a critical role in improving the sensitivity, specificity, and dynamic range of biomarker assays, ultimately contributing to the early detection, prognosis, and personalized treatment of cancer. Further research and innovation in signal amplification technologies are expected to advance the field of cancer diagnostics, enabling the development of more accurate and reliable biomarker detection assays for clinical use.[69]

3. Multiplexed Detection Platforms: Multiplexed detection platforms play a pivotal role in cancer diagnostics by enabling the simultaneous detection of multiple biomarkers from a single sample. These platforms offer several advantages, including enhanced diagnostic accuracy, reduced sample consumption, and increased efficiency compared to single-marker assays. Multiplexed detection can be achieved through various techniques, such as microarray-based assays, bead-based assays, and multiplexed immunoassays.[70] Microarray-based platforms utilize solid supports, such as glass slides or silicon chips, to immobilize multiple capture probes specific to different biomarkers. Upon incubation with the sample, the bound biomarkers are detected using fluorescent or chemiluminescent labels, allowing for simultaneous analysis of multiple analytes. Bead-based assays utilize microspheres or beads, each functionalized with distinct capture molecules targeting specific biomarkers. By mixing different types of beads in a single assay, multiplexed detection of multiple biomarkers can be achieved in a single reaction. Additionally, multiplexed immunoassays leverage the specificity of antibodies to detect multiple biomarkers simultaneously.[71] These assays can be performed using various formats, such as enzyme-linked immunosorbent assays (ELISA), flow cytometry, or multiplexed suspension arrays, enabling high-throughput and multiplexed detection of cancer biomarkers. Multiplexed detection platforms offer valuable insights into the molecular profile of cancers, providing comprehensive information about the disease phenotype and facilitating personalized treatment strategies. Moreover, these platforms have the potential to streamline the diagnostic workflow, reduce costs, and improve patient outcomes by enabling early detection, accurate diagnosis, and monitoring of cancer progression. Continued advancements in multiplexed detection technologies are expected to further enhance their utility in cancer diagnostics, paving the way for more effective and personalized approaches to cancer management.[72]

4. Point-of-Care Diagnostics: Point-of-care diagnostics (POC) refers to medical tests performed at or near the patient's location, providing rapid results that can be used for immediate clinical decision-making. In the context of cancer, POC diagnostics play a crucial role in early detection, monitoring, and management of the disease. These diagnostics offer several advantages, including rapid turnaround time, ease of use, and accessibility, particularly in resource-limited settings.[73] Various POC technologies are employed for cancer diagnostics, including lateral flow assays, microfluidic devices, and portable imaging systems. Lateral flow assays utilize paper-based or membrane-based strips to detect specific biomarkers in biological samples, providing qualitative or semi-quantitative results within minutes. Microfluidic devices leverage microscale channels and chambers to manipulate and analyze small volumes of biological samples, enabling multiplexed detection of cancer biomarkers with high sensitivity and specificity.[74] Portable imaging systems, such as handheld ultrasound devices or smartphone-based microscopy, allow for real-time visualization and analysis of cancerous lesions or abnormalities at the point of care, facilitating early detection and monitoring of disease progression. POC diagnostics offer immense potential for improving cancer care by enabling early diagnosis, guiding treatment decisions, and monitoring therapeutic responses in a timely manner. These technologies empower healthcare providers to deliver personalized and targeted interventions, ultimately improving patient outcomes and reducing healthcare costs. Continued advancements in POC diagnostics, coupled with increased accessibility and affordability, hold promise for revolutionizing cancer management and reducing the global burden of the disease.[75]

Imaging Techniques Employing Plant-Derived Nanoparticles

1. Optical Imaging: Optical imaging is a non-invasive imaging technique that utilizes light to visualize and study biological structures and processes at the cellular and molecular level. In the context of cancer diagnostics, optical imaging plays a crucial role in detecting tumors, monitoring disease progression, and assessing treatment response. This imaging modality encompasses a wide range of techniques, including fluorescence imaging, bioluminescence imaging, and confocal microscopy.[76] Fluorescence imaging involves the use of fluorescent probes or dyes that emit light of specific wavelengths when excited by external light sources, allowing for the visualization of specific molecular targets or biomarkers within tissues or cells. Bioluminescence imaging relies on the detection of light emitted by bioluminescent reporter molecules, such as luciferase, which are expressed within cancer cells or tumor tissues, providing insights into tumor growth and metastasis in vivo. Confocal microscopy utilizes a focused laser beam to generate high-resolution, three-dimensional images of biological samples, enabling detailed visualization of cellular structures and interactions within tissues.[77] Optical imaging techniques offer several advantages for cancer diagnostics, including high sensitivity, real-time imaging capabilities, and the ability to perform longitudinal studies in living organisms. These techniques can facilitate early detection of tumors, guide surgical interventions, and monitor therapeutic responses in preclinical and clinical settings. Moreover, optical imaging can be combined with other imaging modalities, such as computed tomography (CT) or magnetic resonance imaging (MRI), to provide complementary

information and improve diagnostic accuracy. Continued advancements in optical imaging technologies, including the development of novel contrast agents, improved imaging instrumentation, and enhanced image analysis algorithms, hold promise for further enhancing the utility of optical imaging in cancer diagnostics and personalized medicine.[78]

2. Magnetic Resonance Imaging (MRI): Plant-derived nanoparticles can be engineered to exhibit magnetic properties, making them suitable contrast agents for MRI. These magnetic nanoparticles can enhance the contrast between normal and cancerous tissues, enabling non-invasive visualization of tumors and metastatic lesions with high spatial resolution and tissue penetration depth. MRI using plant-derived nanoparticles offers advantages such as real-time imaging, multi-parametric imaging, and functional imaging, providing valuable insights into tumor biology and microenvironment.[79]

3. Computed Tomography (CT) Imaging: Plant-derived nanoparticles can be functionalized with high-Z elements such as gold or bismuth, making them effective contrast agents for CT imaging. These nanoparticles absorb X-rays and enhance the attenuation of X-ray beams, resulting in increased contrast between soft tissues and tumors in CT images. CT imaging using plant-derived nanoparticles offers advantages such as high contrast sensitivity, rapid image acquisition, and three-dimensional visualization of anatomical structures, facilitating accurate diagnosis and staging of cancer.

4. Ultrasound Imaging: Plant-derived nanoparticles can enhance the contrast and sensitivity of ultrasound imaging by acting as acoustic contrast agents. These nanoparticles can be encapsulated within microbubbles or nanoemulsions that resonate in response to ultrasound waves, generating strong acoustic signals that can be detected and quantified using ultrasound scanners. Ultrasound imaging using plant-derived nanoparticles offers advantages such as real-time imaging, non-invasiveness, and cost-effectiveness, making it suitable for dynamic monitoring of tumor response to therapy.[80]

Advantages and Challenges in Using Plant-Derived Nanoparticles for Cancer Diagnostics

a. Biocompatibility: Plant-derived nanoparticles are composed of natural plant-based materials that are biocompatible and biodegradable, minimizing toxicity and adverse effects in living organisms. Unlike synthetic nanoparticles, which may elicit immune responses or accumulate in organs, plant-derived nanoparticles are well-tolerated by the body, reducing the risk of inflammation or allergic reactions. This biocompatibility makes them suitable for various biomedical applications, including drug delivery, imaging, and diagnostics, without causing harm to the surrounding tissues or organs.[81]

b. Targeting Specificity: Plant-derived nanoparticles can be functionalized with targeting ligands or antibodies that selectively bind to cancer cells or specific biomarkers, enhancing the specificity of diagnostic assays and imaging techniques. By conjugating targeting moieties onto the surface of nanoparticles, researchers can direct them to the desired site of action, minimizing off-target effects and improving the accuracy of cancer detection and localization. This targeting specificity enables precise delivery of therapeutic agents to tumor tissues, maximizing therapeutic efficacy while minimizing systemic toxicity to healthy tissues.

c. Signal Amplification: Plant-derived nanoparticles can amplify detection signals through various signal amplification strategies, enabling sensitive and quantitative detection of cancer biomarkers in biological samples. By conjugating signaling molecules or amplification probes onto the surface of nanoparticles, researchers can enhance the sensitivity and specificity of diagnostic assays, enabling detection of low-abundance biomarkers with high precision. This signal amplification capability improves the accuracy of cancer diagnosis and enables early detection of disease, leading to better patient outcomes and treatment strategies.[82]

d. Multiplexed Detection: Plant-derived nanoparticles can be integrated into multiplexed detection platforms that simultaneously detect multiple cancer biomarkers from a single sample, providing comprehensive molecular information about the cancer phenotype. By functionalizing nanoparticles with different recognition elements or reporter molecules, researchers can create multiplexed biosensors capable of profiling multiple biomarkers in parallel, enabling comprehensive molecular profiling of tumors and personalized treatment strategies. This multiplexed detection approach enhances the efficiency and throughput of diagnostic assays, enabling rapid screening and characterization of cancer samples with minimal sample volume and processing time.

e. Point-of-Care Testing: Plant-derived nanoparticles enable rapid and portable point-of-care testing platforms that can be deployed in resource-limited settings, facilitating early detection and screening of cancer in underserved populations. By incorporating nanoparticles into paper-based or microfluidic devices, researchers can develop low-cost, user-friendly diagnostic tests that provide rapid results without the need for specialized equipment or trained personnel. This point-of-care testing approach improves access to cancer diagnostics in remote or rural areas, enabling timely intervention and treatment initiation for patients with limited healthcare resources.[83]

Challenges

a. Synthesis Complexity: The synthesis and modification of plant-derived nanoparticles can be complex and require specialized expertise, equipment, and resources, limiting their widespread adoption and scalability.

Researchers often encounter challenges in controlling nanoparticle size, shape, and surface properties, as well as optimizing reaction conditions and purification methods. Additionally, the synthesis of plant-derived nanoparticles may involve multiple steps and require access to plant-derived materials, which may vary in composition and quality, further complicating the process. Addressing these challenges requires interdisciplinary collaboration, innovation in nanomaterial synthesis techniques, and the development of scalable manufacturing processes that can meet the growing demand for nanoparticle-based technologies.

b. Stability and Shelf-Life: Plant-derived nanoparticles may exhibit limited stability and shelf-life, particularly in biological matrices or harsh physiological environments, which can affect their performance in diagnostic assays and imaging techniques. Factors such as aggregation, degradation, and interactions with biological components can compromise the stability of nanoparticles and lead to loss of function over time. Researchers must optimize nanoparticle formulations, storage conditions, and packaging strategies to enhance stability and prolong shelf-life, ensuring consistent performance and reliability in clinical applications. Additionally, the development of stabilizing agents, encapsulation methods, and surface modifications may help mitigate stability issues and improve the robustness of plant-derived nanoparticles for biomedical use.[84]

c. Regulatory Approval: Plant-derived nanoparticles face regulatory challenges related to safety, quality control, and approval for clinical use, requiring rigorous preclinical and clinical studies to demonstrate their efficacy and safety for cancer diagnostics. Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have specific guidelines for the evaluation and approval of nanoparticle-based products, including requirements for preclinical characterization, toxicology studies, and clinical trials. Researchers must navigate complex regulatory pathways, adhere to regulatory standards, and generate comprehensive data on nanoparticle safety, efficacy, and quality to obtain regulatory approval for clinical use. Close collaboration between researchers, regulators, and industry partners is essential to streamline the regulatory process and accelerate the translation of plant-derived nanoparticles from bench to bedside.[85]

d. Cost-Effectiveness: The cost of producing plant-derived nanoparticles may be higher than conventional biomarkers or synthetic nanoparticles, posing challenges to affordability and accessibility, particularly in low-resource settings. Factors such as raw material costs, synthesis complexity, purification methods, and quality control measures contribute to the overall cost of nanoparticle production. Researchers must explore cost-effective synthesis methods, optimize manufacturing processes, and scale up production capabilities to reduce the cost of plant-derived nanoparticles and make them more accessible to patients worldwide. Additionally, innovative financing models, public-private partnerships, and technology transfer agreements may help overcome financial barriers and promote equitable access to nanoparticle-based cancer diagnostics and therapy.

e. Standardization and Validation: There is a need for standardized protocols and validation procedures for the synthesis, characterization, and application of plant-derived nanoparticles in cancer diagnostics, ensuring reproducibility, reliability, and accuracy across different research studies and clinical settings. Variability in nanoparticle synthesis methods, characterization techniques, and assay conditions can lead to inconsistencies in nanoparticle performance and data interpretation, hindering the comparability and reliability of research findings. Researchers must establish standardized protocols for nanoparticle synthesis, characterization, and functionalization, as well as develop reference materials and proficiency testing programs to validate nanoparticle-based assays and imaging techniques. Collaboration between academia, industry, and regulatory agencies is essential to establish consensus standards, promote data sharing, and facilitate technology transfer, enabling the widespread adoption and acceptance of plant-derived nanoparticles in cancer diagnostics and therapy.[86]

Plant-Derived Nanoparticles in Cancer Therapy

A. Drug Delivery Systems Utilizing Plant-Derived Nanoparticles

1. Nanoparticle-Based Drug Delivery: Nanoparticles derived from plants have emerged as promising candidates for delivering drugs in cancer treatment, owing to their biocompatibility, biodegradability, and potential for targeted delivery to tumor sites. These nanoparticles have the capability to encapsulate or bind therapeutic substances, such as chemotherapy drugs, nucleic acids, or targeted therapies, and transport them selectively to cancerous cells, thereby minimizing the toxicity to healthy tissues.

2. Encapsulation and Protection: Nanoparticles derived from plants have the capability to encapsulate hydrophobic medications within their lipid bilayers or hydrophilic medications within their aqueous cores, safeguarding them from degradation and premature release in bodily fluids. This encapsulation yields sustained drug release kinetics, prolonged circulation time, and heightened bioavailability, thereby enhancing the therapeutic effectiveness of anticancer medications and diminishing off-target effects.[87]

3. Active Targeting Strategies: Nanoparticles sourced from plants have the capacity to undergo functionalization with targeting ligands or antibodies that identify specific receptors or biomarkers excessively expressed on the surface of cancer cells. This functionalization enables active targeting and internalization of nanoparticles into tumor cells through

receptor-mediated endocytosis. Such a targeted approach boosts the accumulation of therapeutic agents within tumor tissues while minimizing exposure to healthy tissues, thereby maximizing therapeutic efficacy and reducing systemic toxicity.[88]

4. Passive Targeting via Enhanced Permeability and Retention (EPR) Effect: Nanoparticles derived from plants can utilize the enhanced permeability and retention (EPR) effect, which pertains to the abnormal blood vessel formation and compromised lymphatic drainage in tumor tissues, to passively gather within tumors following systemic administration. By leveraging the EPR effect, nanoparticles can accumulate selectively within tumor tissues, resulting in higher local drug concentrations and improved therapeutic outcomes.

B. Targeted Therapy and Controlled Release Mechanisms

1. Targeted Therapy: Plant-derived nanoparticles enable targeted therapy approaches that specifically inhibit molecular targets or signaling pathways involved in cancer development and progression. These nanoparticles can be conjugated with monoclonal antibodies, small-molecule inhibitors, or nucleic acid therapeutics that selectively bind to cancer-specific antigens or biomarkers, triggering cellular apoptosis, growth inhibition, or immune-mediated cytotoxicity. By precisely delivering therapeutic agents to cancer cells while sparing healthy tissues, targeted therapy using plant-derived nanoparticles can enhance treatment efficacy and minimize off-target effects, improving patient outcomes and quality of life.[89]

2. Controlled Release Mechanisms: Plant-derived nanoparticles offer precise control over drug release kinetics through various mechanisms, including diffusion, degradation, and stimulus-responsive behaviors. By modulating the physicochemical properties of nanoparticles, such as size, shape, surface charge, and composition, researchers can tailor drug release profiles to achieve sustained, pulsatile, or triggered release of therapeutic agents within tumor tissues, optimizing therapeutic efficacy and minimizing off-target effects. This controlled release capability allows for the delivery of therapeutic payloads at therapeutically relevant concentrations over extended periods, enhancing drug bioavailability and minimizing systemic toxicity.

3. Stimulus-Responsive Nanoparticles: Nanoparticles derived from plants can be tailored to react to specific stimuli within the tumor microenvironment, such as pH, temperature, redox potential, or enzymatic activity, prompting targeted drug release at the site of action. Responsive nanoparticles can be designed to undergo structural changes, disintegrate, or release payloads in response to external or internal signals, offering precise control over drug delivery dynamics and enhancing therapeutic precision. This responsive behavior enables dynamic modulation of drug release in response to changes in the tumor microenvironment, improving the efficacy of cancer therapy and overcoming drug resistance mechanisms.[90]

4. Combination Therapies: Plant-derived nanoparticles enable combination therapies that co-deliver multiple therapeutic agents, such as chemotherapeutic drugs, immunomodulators, and targeted therapies, to synergistically target different aspects of cancer biology and overcome drug resistance mechanisms. By encapsulating or conjugating multiple drugs within nanoparticles, researchers can achieve synergistic effects, minimize drug interactions, and overcome pharmacokinetic limitations, enhancing therapeutic efficacy and prolonging patient survival. Combination therapy using plant-derived nanoparticles holds promise for overcoming treatment resistance, reducing tumor burden, and improving overall response rates in cancer patients, highlighting their potential as versatile platforms for advanced cancer therapy strategies.[91]

C. Therapeutic Efficacy and Challenges in Clinical Translation

1. Therapeutic Efficacy

Plant-derived nanoparticles have demonstrated promising therapeutic efficacy in preclinical studies across various cancer models, including solid tumors, hematological malignancies, and metastatic diseases. These nanoparticles have been shown to enhance the accumulation and retention of therapeutic agents within tumor tissues, improve drug bioavailability, and overcome multidrug resistance mechanisms, leading to enhanced tumor regression, prolonged survival, and improved quality of life in animal models.

2. Challenges in Clinical Translation

Despite the significant preclinical success of plant-derived nanoparticles in cancer therapy, several challenges must be addressed for their successful clinical translation.

a. Safety and Toxicity: The safety profile of plant-derived nanoparticles must be rigorously evaluated in preclinical studies to assess their biocompatibility, immunogenicity, biodistribution, and long-term toxicity. Concerns regarding potential adverse effects, such as inflammation, immunotoxicity, and organ toxicity, must be addressed to ensure patient safety in clinical trials.[92]

b. Pharmacokinetics and Pharmacodynamics: The pharmacokinetic and pharmacodynamic properties of plant-derived nanoparticles, including their circulation half-life, tissue distribution, metabolism, and clearance, must be characterized to optimize dosing regimens and treatment schedules for clinical use. Strategies to enhance nanoparticle stability, prolong circulation time, and improve tumor targeting efficiency are essential for maximizing therapeutic efficacy and minimizing off-target effects.

c. Scalability and Manufacturing: Scalable and reproducible manufacturing processes are required to produce plant-derived nanoparticles in large quantities for clinical trials and commercialization. Standardized protocols, quality control measures, and good manufacturing practices (GMP) are essential to ensure batch-to-batch consistency, product quality, and regulatory compliance throughout the manufacturing process.

d. Regulatory Approval and Clinical Validation: Plant-derived nanoparticles face regulatory challenges related to safety, efficacy, quality control, and approval for clinical use. Rigorous preclinical studies, followed by well-designed clinical trials, are necessary to establish the therapeutic efficacy, safety profile, and clinical benefit of plant-derived nanoparticles in cancer therapy. Collaboration between academia, industry, and regulatory agencies is crucial to expedite the translation of plant-derived nanoparticles from bench to bedside.[93]

e. Cost-Effectiveness and Accessibility: The cost-effectiveness and accessibility of plant-derived nanoparticles must be evaluated to ensure equitable access to cancer therapy for all patients, regardless of socioeconomic status or geographic location. Strategies to reduce production costs, improve scalability, and optimize resource utilization are essential for maximizing the affordability and availability of plant-derived nanoparticles in clinical practice.

Future Directions and Challenges

A. Potential Advancements in Plant-Derived Nanoparticle Research for Cancer Applications

1. Enhanced Targeting Strategies: Future research in plant-derived nanoparticle technology may focus on refining targeting strategies to improve the specificity and efficiency of cancer therapy. This could involve the development of novel targeting ligands or antibodies that recognize cancer-specific biomarkers with high affinity, as well as the incorporation of stimuli-responsive elements that enable precise control over nanoparticle localization and drug release within tumor tissues. Additionally, advancements in nanomaterial design and surface engineering techniques may enable the creation of nanoparticles with enhanced targeting capabilities, allowing for selective accumulation and uptake by cancer cells while minimizing interactions with healthy tissues. By optimizing targeting strategies, researchers can enhance the therapeutic efficacy of plant-derived nanoparticles and overcome challenges associated with off-target effects and systemic toxicity, paving the way for more effective cancer treatments.[94]

2. Multifunctional Nanoparticles: Researchers may explore the design of multifunctional plant-derived nanoparticles capable of integrating diagnostic, therapeutic, and imaging functionalities within a single platform. By combining drug delivery, imaging, and therapeutic targeting capabilities, these nanoparticles could enable comprehensive cancer management strategies, such as image-guided surgery, real-time monitoring of treatment response, and personalized therapy optimization. Furthermore, incorporating multiple functionalities into a single nanoparticle platform offers numerous benefits, including enhanced treatment efficacy, simplified treatment protocols, and increased patient comfort. Multifunctional nanoparticles hold the potential to transform cancer diagnosis and treatment by furnishing healthcare providers with valuable insights into tumor characteristics, treatment response, and disease progression. This, in turn, facilitates more informed clinical decision-making and contributes to better patient outcomes.

3. Combination Therapies: The development of combination therapies using plant-derived nanoparticles could represent a promising approach for overcoming drug resistance mechanisms and enhancing therapeutic efficacy. By co-delivering synergistic drug combinations or combining nanoparticles with other treatment modalities such as immunotherapy or radiotherapy, researchers may achieve superior tumor control and improved patient outcomes in various cancer types. Combination therapy strategies leverage the complementary mechanisms of action of different therapeutic agents, allowing for enhanced tumor cell killing, reduced treatment resistance, and prolonged patient survival. Plant-derived nanoparticles offer a versatile platform for combination therapy delivery, enabling the simultaneous administration of multiple drugs with distinct pharmacological properties and synergistic effects. By optimizing combination therapy regimens, researchers can maximize treatment efficacy while minimizing adverse effects, offering new hope for patients with challenging-to-treat cancers.

4. Nanoparticle Engineering and Optimization: Advances in nanotechnology and materials science may lead to the development of novel nanoparticle formulations with optimized physicochemical properties, such as size, shape, surface charge, and stability. By fine-tuning these parameters, researchers can enhance nanoparticle circulation time, tumor accumulation, cellular uptake, and intracellular drug release, leading to improved therapeutic outcomes and reduced off-target effects. Furthermore, advancements in nanoparticle engineering techniques, such as bottom-up synthesis approaches, self-assembly methods, and surface modification strategies, may enable the creation of nanoparticles with tailored properties and functionalities optimized for specific cancer applications. Nanoparticle optimization efforts aim to overcome existing limitations in nanoparticle-based cancer therapies, such as poor bioavailability, limited tumor penetration, and rapid clearance from the body, thereby improving treatment efficacy and patient outcomes. Continued research and innovation in nanoparticle engineering and optimization are essential for unlocking the full potential of plant-derived nanoparticles in cancer therapy and advancing

personalized medicine approaches.[95]

5. Personalized Medicine Approaches: Future research may focus on the integration of plant-derived nanoparticle technology with personalized medicine approaches, such as patient-specific biomarker profiling, genomic analysis, and therapeutic response prediction. By tailoring nanoparticle formulations and treatment regimens to individual patient characteristics, researchers can optimize treatment outcomes, minimize adverse effects, and maximize therapeutic benefit in a personalized and precision-oriented manner. Personalized medicine approaches aim to identify patient-specific factors that influence treatment response and disease progression, allowing for tailored interventions that address the unique needs and preferences of each patient. Plant-derived nanoparticles offer a versatile platform for personalized medicine applications, enabling the customization of treatment strategies based on patient-specific biomarkers, genetic mutations, and clinical characteristics. By integrating personalized medicine principles into nanoparticle-based cancer therapies, researchers can optimize treatment efficacy, reduce treatment-related toxicity, and improve patient outcomes, ushering in a new era of precision oncology.

B. Regulatory Considerations and Safety Concerns

1. Safety Assessment: Regulatory agencies will require comprehensive safety assessments of plant-derived nanoparticles before their approval for clinical use. Preclinical studies must evaluate the biocompatibility, immunogenicity, biodistribution, and long-term toxicity of nanoparticles in animal models, addressing concerns such as inflammation, organ toxicity, and off-target effects. Rigorous safety testing is essential to ensure patient safety and regulatory compliance throughout the drug development process. Furthermore, researchers must investigate potential risks associated with nanoparticle administration, including immune reactions, allergic responses, and unexpected pharmacological effects, to mitigate safety concerns and ensure the safe use of plant-derived nanoparticles in clinical settings. Long-term monitoring and surveillance programs may also be necessary to assess the safety profile of nanoparticle-based therapies in real-world patient populations and identify any unforeseen adverse events or complications.[96]

2. Manufacturing Standards: Standardized manufacturing protocols and quality control measures are necessary to ensure the reproducibility, consistency, and quality of plant-derived nanoparticles for clinical use. Good manufacturing practices (GMP) guidelines should be followed to maintain product quality, purity, and stability, while minimizing batch-to-batch variability and contamination risks. Manufacturing facilities must adhere to regulatory standards and undergo regular inspections to ensure compliance with quality assurance requirements. Additionally, researchers must establish robust quality control procedures and validation protocols to verify the integrity and performance of nanoparticle formulations throughout the manufacturing process, from raw material selection to final product packaging. By implementing stringent manufacturing standards and quality assurance measures, researchers can ensure the reliability, safety, and efficacy of plant-derived nanoparticles for cancer therapy, enhancing confidence in their clinical utility and regulatory approval.

3. Regulatory Approval Pathways: Regulatory approval pathways for plant-derived nanoparticles may vary depending on their intended use, therapeutic indication, and novelty. Researchers and manufacturers must navigate complex regulatory frameworks and submit comprehensive regulatory submissions that demonstrate the safety, efficacy, and quality of nanoparticles for cancer therapy. Close collaboration with regulatory agencies and early engagement in the regulatory process are essential for expediting approval timelines and overcoming regulatory hurdles. Furthermore, researchers must stay abreast of evolving regulatory requirements and guidance documents related to nanoparticle-based therapies, ensuring compliance with applicable regulations and standards. By proactively addressing regulatory considerations and engaging with regulatory stakeholders, researchers can streamline the approval process and accelerate the translation of plant-derived nanoparticles from bench to bedside, facilitating timely access to innovative cancer treatments for patients in need.[97]

4. Risk-Benefit Assessment: Regulatory agencies will conduct risk-benefit assessments to evaluate the potential benefits and risks of plant-derived nanoparticles for cancer therapy. Factors such as therapeutic efficacy, safety profile, patient population, and unmet medical need will be considered in the regulatory decision-making process. Researchers must provide robust clinical data and evidence of therapeutic benefit to justify the use of plant-derived nanoparticles in cancer treatment and obtain regulatory approval. Additionally, researchers should assess the risk-benefit profile of nanoparticle-based therapies in comparison to existing treatment options, weighing the potential advantages of nanoparticle delivery against potential risks and uncertainties. Transparency and communication with regulatory agencies and healthcare stakeholders are critical to ensuring a comprehensive understanding of the risk-benefit profile of plant-derived nanoparticles and facilitating informed decision-making regarding their clinical use.

C. Addressing Challenges and Limitations for Widespread Adoption

1. Cost-Effectiveness: The cost-effectiveness of plant-derived nanoparticles must be addressed to ensure their affordability and accessibility for patients, healthcare providers, and payers. Strategies to reduce production

costs, improve manufacturing efficiency, and optimize resource utilization are essential for maximizing the cost-effectiveness of nanoparticle-based cancer therapies and minimizing financial barriers to patient access. This may involve leveraging economies of scale, implementing process optimization techniques, and exploring alternative raw materials and synthesis methods that offer cost savings without compromising product quality or performance. Additionally, health economic analyses and reimbursement strategies may help demonstrate the value proposition of nanoparticle-based therapies to healthcare payers and facilitate reimbursement decisions, ensuring sustainable market access and uptake.[98]

2. Scalability and Manufacturing: Scalable manufacturing processes are needed to produce plant-derived nanoparticles in large quantities for clinical trials and commercialization. Researchers must optimize synthesis methods, scale-up production capabilities, and establish robust manufacturing protocols that meet regulatory requirements and ensure product quality, consistency, and reproducibility. Collaboration with industry partners and contract manufacturing organizations (CMOs) may facilitate technology transfer and accelerate scale-up efforts. Furthermore, investment in infrastructure, equipment, and personnel training may be necessary to build manufacturing capacity and capability, particularly in regions with limited resources or expertise in nanoparticle production. By addressing scalability and manufacturing challenges, researchers can ensure the timely translation of nanoparticle-based therapies from the laboratory to the clinic, enabling broader patient access and impact.[99]

3. Clinical Translation and Adoption: Overcoming barriers to clinical translation and adoption requires interdisciplinary collaboration, stakeholder engagement, and strategic partnerships across academia, industry, healthcare providers, regulatory agencies, and patient advocacy groups. Researchers must conduct well-designed clinical trials, generate robust clinical evidence, and demonstrate the clinical benefit of plant-derived nanoparticles in cancer therapy. Education, awareness, and training programs may help healthcare providers and patients understand the potential benefits and risks of nanoparticle-based therapies and encourage their adoption in clinical practice. Additionally, initiatives to streamline regulatory pathways, expedite approval processes, and incentivize innovation in nanoparticle research and development may facilitate the translation of promising nanoparticle-based technologies into clinically viable products, improving patient outcomes and healthcare delivery.[100]

4. Global Access and Equity: Ensuring global access and equity to nanoparticle-based cancer therapies requires addressing disparities in healthcare infrastructure, resources, and funding across different regions and healthcare systems. Collaborative efforts between governments, international organizations, non-profit organizations, and philanthropic foundations may facilitate technology transfer, capacity building, and resource mobilization to support the implementation of nanoparticle-based cancer therapies in low- and middle-income countries.[101] Additionally, innovative financing mechanisms, such as public-private partnerships and technology transfer agreements, may help overcome financial barriers and promote equitable access to cancer care worldwide. By prioritizing global health equity and fostering international collaboration, stakeholders can work together to address the unmet medical needs of underserved populations and ensure that nanoparticle-based cancer therapies reach those who need them most, regardless of geography or socioeconomic status.[102]

CONCLUSION

Nanoparticles derived from plant extracts show great promise in cancer diagnostics and therapy. Their distinct characteristics, along with their environmentally friendly synthesis methods, make them appealing for the creation of novel cancer treatment and diagnostic methods. The versatility and targeting abilities of these nanoparticles provide opportunities for precise and personalized cancer diagnosis and therapy. As research progresses in this field, plant extract-based nanoparticles are expected to become increasingly important in cancer care, offering avenues for more efficient and sustainable strategies to address this challenging disease. Moreover, the role of plant-derived nanoparticles in cancer diagnostics, including biomarker detection and imaging techniques, has been examined, along with their potential in targeted therapy and controlled drug delivery mechanisms. Challenges such as regulatory considerations, safety concerns, and limitations for widespread adoption have also been addressed. The implications of plant-derived nanoparticles in advancing cancer diagnostics and therapy are profound, offering opportunities for enhanced targeting, improved therapeutic efficacy, and personalized medicine approaches. Future prospects include potential advancements in nanoparticle research, regulatory frameworks, and manufacturing standards to overcome existing challenges and accelerate clinical translation. Recommendations for further research involve exploring multifunctional nanoparticles, combination therapies, and personalized medicine approaches to optimize cancer treatment outcomes and promote equitable access to nanoparticle-based therapies worldwide. Overall, plant-derived nanoparticles hold immense promise as versatile platforms for cancer diagnosis and therapy, with the potential to transform the landscape of oncology and improve patient outcomes in the years to come.

REFERENCES

1. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv. Drug Deliv. Rev., 1996; 21: 107–116. 10.1016/S0169-409X(96)00401-2.
2. Van Butsele K, Sibret P, Fustin CA, Gohy JF, Passirani C, Benoit J-P, Jerome R, Jerome C. Synthesis and pH-dependent micellization of

diblock copolymer mixtures. J. Colloid Interface Sci., 2009; 329: 235–243. 10.1016/j.jcis.2008.09.080.
3. Yang X, Li ZJ, Wang N, Li L, Song L, He T, Sun L, Wang Z, Wu Q, Luo N, Yi C, Gong C. Curcumin-encapsulated polymeric micelles suppress the development of colon cancer in vitro and in vivo. Scientific Reports, 2015; 5: 10322.10.1038 /srep10322.
4. Bhatt P, Singh S, Alfuraiji N, Al-Snafi AE. CRISPR CAS9: A new technology to modify genome-A review. Open J. Syst. Demonstr. J., 2022; 8(4): 208-15.
5. Liang Y, Deng X, Zhang L, Peng X, Gao W, Cao J, Gu Z, He B. Terminal modification of polymeric micelles with π-conjugated moieties for efficient anticancer drug delivery. Biomaterials, 2015; 71: 1–10. 10.1016/j.biomaterials.2015.08.032.
6. Makino J, Cabral H, Miura Y, Matsumoto Y, Wang M, Kinoh H, Mochida Y, Nishiyama N, Kataoka K. cRGD-installed polymeric micelles loading platinum anticancer drugs enable cooperative treatment against lymph node metastasis. J. Control. Release, 2015; 220. Part B, 783–791. 10.1016/j.jconrel.2015.10.017.
7. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res., 2002; 8: 1284–1291.
8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009; 324: 1029–1033. 10.1126/science.1160809.
9. Wang T, Wang D, Yu H, Wang M, Liu J, Feng B, Zhou F, Yin Q, Zhang Z, Huang Y, Li Y. Intracellularly acid-switchable multifunctional micelles for combinational photo/chemotherapies of the drug-resistant tumor. ACS Nano, 2016; 10: 3496–3508. 10.1021/acsnano.5b07706.
10. Yang TH, Li F, Zhang HT, Fan L, Qiao Y, Tan G, Zhang H, Wu H. Multifunctional pH-sensitive micelles for tumor-specific uptake and cellular delivery. Polym. Chem. UK, 2015; 6: 1373–1382. 10.1039/C4PY01403K.
11. Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapies. Mater. Sci. Eng. C., 2016; 60: 569–578. 10.1016/j.msec.2015.11.067.
12. Devulapally R, Paulmurugan R. Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol, 2014; 6: 40–60. 10.1002/wnan.1242.
13. Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, Severini GM. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Curr. Med. Chem, 2013; 20: 2212–2225. 10.2174/0929867311320170006.
14. Patil YB, Toti US, Khdair A, Ma L, Panyam J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials, 2009; 30: 859–866. 10.1016/j.biomaterials.2008.09.056.
15. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control. Release, 1999; 57: 171–185. 10.1016/S0168-3659(98)00116-3.
16. Wang G, Chen Y, Wang P, Wang Y, Hong H, Li Y, Qian J, Yuan Y, Yu B, Liu C. Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(d,l-lactic acid). Acta Biomater, 2016; 29: 248–260. 10.1016/j.actbio.2015.10.017.
17. Tam YT, To KKW, Chow AHL. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery. Colloids Surf. B Biointerfaces, 2016; 139: 249–258. 10.1016/j.colsurfb.2015.12.026.
18. Owen SC, Patel N, Logie J, Pan G, Persson H, Moffat J, Sidhu SS, Shoichet MS. Targeting HER2 + breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. J. Control. Release, 2013; 172: 395–404. 10.1016/j.jconrel.2013.07.011.
19. Liu Y, Chen Z, Liu C, Yu D, Lu Z, Zhang N. Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials, 2011; 32: 5167–5176. 10.1016/j.biomaterials.2011.03.077.
20. Luo CJ, Okubo T, Nangrejo M, Edirisinghe M. Preparation of polymeric nanoparticles by novel electrospray nanoprecipitation. Polym. Int., 2015; 64: 183–187. 10.1002/pi.4822.
21. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, Préat V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control. Release, 2009; 133: 11–17. 10.1016/j.jconrel.2008.09.086.
22. Mangraviti A, Tzeng SY, Kozielski KL, Wang Y, Jin Y, Gullotti D, Pedone M, Buaron N, Liu A, Wilson DR, Hansen SK, Rodriguez FJ, Gao GD, DiMeco F, Brem H, Olivi A, Tyler B, Green JJ. Polymeric nanoparticles for nonviral gene therapies extend brain tumor survival in vivo. ACS Nano, 2015; 9: 1236–1249. 10.1021/nn504905q.
23. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapies. Nat. Nano, 2007; 2: 751–760. 10.1201/9780429399039-2.
24. Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapies. J. Control. Release, 2012; 162: 225–232. 10.1016/j.jconrel.2012.06.019.

25. Rengan AK, Jagtap M, De A, Banerjee R, Srivastava R. Multifunctional gold coated thermo-sensitive liposomes for multimodal imaging and photo-thermal therapies of breast cancer cells. Nanoscale, 2014; 6: 916–923. 10.1039/C3NR04448C.
26. Jaafar-Maalej C, Charcosset C, Fessi H. A new method for liposome preparation using a membrane contactor. J. Liposome Res., 2011; 21: 213–220. 10.3109/08982104.2010.517537.
27. Marcato PD, Duran N. New aspects of nanopharmaceutical delivery systems. J. Nanosci. Nanotechnol, 2008; 8: 2216–2229. 10.1166/jnn.2008.274.
28. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapies: 15 years along the road. Drug Discov. Today, 2012; 17: 160–166. 10.1016/j.drudis.2011.09.015.
29. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomed, 2012; 7: 49–60.
30. Zhao Y, Ren W, Zhong T, Zhang S, Huang D, Guo Y, Yao X, Wang C, Zhang WQ, Zhang X, Zhang Q. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J. Control. Release, 2016; 222: 56–66. 10.1016/j.jconrel.2015.12.006.
31. Chiang Y-T, Lo C-L. pH-Responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapies. Biomaterials, 2014; 35: 5414–5424. 10.1016/j.biomaterials.2014.03.046.
32. Ren L, Chen S, Li H, Zhang Z1, Zhong J1, Liu M1, Zhou X. MRI-guided liposomes for targeted tandem chemotherapies and therapeutic response prediction. Acta Biomater, 2016; 35: 260–268. 10.1016/j.actbio.2016.02.011.
33. German SV, Navolokin NA, Kuznetsova NR, Zuev VV, Inozemtseva OA, Anis'kov AA, Volkova EK, Bucharskaya AB, Maslyakova GN, Fakhrullin RF, Terentyuk GS, Vodovozova EL, Gorin DA. Liposomes loaded with hydrophilic magnetite nanoparticles: preparation and application as contrast agents for magnetic resonance imaging. Colloids Surf. B Biointerfaces, 2015; 135: 109–115. 10.1016/j.colsurfb.2015.07.042.
34. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapies: a concise review with emphasis on dendrimers. Int. J. Nanomed. 2009; 4: 1–7. 10.2147/IJN.S4241.
35. Somani S, Dufes C. Applications of dendrimers for brain delivery and cancer therapies. Nanomedicine, 2014; 9: 2403–2414. 10.2217/nnm.14.130
36. Bhatt P, Kumar V, Rastogi H, Malik MK, Dixit R, Garg S, et al. Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch. ACS Omega [Internet], 2023; 8(33): 30294–305. Available from: http://dx.doi.org/10.1021/acsomega.3c03158.
37. Cai X, Hu J, Xiao J, Cheng Y. Dendrimer and cancer: a patent review (2006-present). Exp. Opin. Ther. Pat., 2013; 23: 515–529. 10.1517/13543776.2013.761207.
38. Newkome GR, Shreiner CD. Poly(amidoamine), polypropylenimine, and related dendrimers and dendrons possessing different 1→2 branching motifs: an overview of the divergent procedures. Polymer, 2008; 49: 1–173. 10.1016/j.polymer.2007.10.021.
39. Ahamed S, Bhatt P, Sultanuddin SJ, Walia R, Haque MA, InayathAhamed SB. An Intelligent IoT enabled Health Care Surveillance using Machine Learning. In: 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
40. Bhatt P, Singh S, Kumar Sharma S, Rabiu S. Development and characterization of fast dissolving buccal strip of frovatriptan succinate monoydrate for buccal delivery. Int J Pharm Investig [Internet], 2021; 11(1): 69–75. Available from: http://dx.doi.org/10.5530/ijpi.2021.1.13
41. Al-Snafi AE, Singh S, Bhatt P, Kumar V. A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity. GSC biol pharm sci [Internet], 2022; 19(3): 148–55. Available from: http://dx.doi.org/10.30574/gscbps.2022.19.3.0231.
42. Singh S, Bhatt P, Alfuraiji N, Thuwaini MM, Snafi AE. Cardiovascular comorbidity of COVID-19 disease: A review. WJPMR, 2022; 8(4): 216–25.
43. Khoee S, Hemati K. Synthesis of magnetite/polyamino-ester dendrimer based on PCL/PEG amphiphilic copolymers via convergent approach for targeted diagnosis and therapies. Polymer, 2013; 54: 5574–5585. 10.1016/j.polymer.2013.07.074.
44. Grayson SM, Frechet JM. Convergent dendrons and dendrimers: from synthesis to applications. Chem. Rev., 2001; 101: 3819–3868. 10.1021/cr990116h.
45. Bhatt P, Kumar V, Subramaniyan V, Nagarajan K, Sekar M, Chinni SV, et al. Plasma modification techniques for natural polymer-based drug delivery systems. Pharmaceutics [Internet], 2023; 15(8). Available from: http://dx.doi.org/10.3390/pharmaceutics15082066.
46. Liu Y, Ng Y, Toh MR, Chiu GNC. Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer. J. Control. Release, 2015; 220. Part A, 438–446. 10.1016/j.jconrel.2015.11.004.
47. Cheng L, Hu Q, Cheng L, Hu W, Xu M, Zhu Y, Zhang L, Chen D. Construction and evaluation of PAMAM-DOX conjugates with superior tumor recognition and intracellular acid-triggered drug release properties. Colloids Surf. B Biointerfaces, 2015; 136: 37–45. 10.1016/j.colsurfb.2015.04.003.
48. Liu X, Liu C, Chen C, Bentobji M, Cheillan FA, Piana JT, Qu F, Rocchi P, Peng L. Targeted delivery of Dicer-substrate siRNAs using a dual targeting

peptide decorated dendrimer delivery system. Nanomed. Nanotechnol. Biol. Med, 2014; 10: 1627–1636. 10.1016/j.nano.2014.05.008.
49. Wang H, Zheng L, Peng C, Guo R, Shen M, Shi X, Zhang G. Computed tomography imaging of cancer cells using acetylated dendrimer-entrapped gold nanoparticles. Biomaterials, 2011; 32: 2979–2988. 10.1016 /j.biomaterials.2011.01.001
50. Li KA, Wen SH, Larson AC, Shen M, Zhang Z, Chen Q, Shi X, Zhang G. Multifunctional dendrimer-based nanoparticles for in vivo MR/CT dual-modal molecular imaging of breast cancer. Int. J. Nanomed, 2013; 8: 2589–2600. 10.2147/IJN.S46177.
51. Wang ZB, Jiang H, Xia YG, Yang BY, Kuang HX. α-Glucosidase inhibitory constituents from Acanthopanax senticosus harm leaves. Molecules, 2012; 17(6): 6269–6276.
52. Chin WW, Parmentier J, Widzinski M, Tan EH, Gokhale R. A brief literature and patent review of nanosuspensions to a final drug product. J Pharm Sci., 2014; 103(10): 2980–2999. [DOI](https://doi.org/10.1002/jps.24098)
53. Hwang KA, Park MA, Kang NH, Yi BR, Hyun SH, Jeung EB, Choi KC. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor alpha and insulin-like growth factor-1 receptor signaling pathways. Toxicol Appl Pharmacol, 2013; 272(3): 637–646.
54. Choi EJ, Jung JY, Kim GH. Genistein inhibits the proliferation and differentiation of MCF-7 and 3T3-L1 cells via the regulation of ERα expression and induction of apoptosis. Exp Ther Med, 2014; 8(2): 454–458.
55. Pankaj. Cyclodextrin modified block polymer for oral chemotherapy. J Pharm Res Int [Internet], 2021; 21–9. Available from: http://dx.doi.org/10.9734 /jpri/2020/v32i3831009.
56. Luo Y, Wang SX, Zhou ZQ, Wang Z, Zhang YG, Zhang Y, Zhao P. Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor- kappa B (NF-κB) pathway. Tumour Biol., 2014; 35(11): 11483–11488.
57. Yamasaki M, Mine Y, Nishimura M, Fujita S, Sakakibara Y, Suiko M, Morishita K, Nishiyama K. Genistein induces apoptotic cell death associated with inhibition of the NF-κB pathway in adult T-cell leukaemia cells. Cell Bio Int., 2013; 37(7): 742–747. [DOI](https://doi.org/10.1002/cbin.10101)
58. Zhang Z, Wang CZ, Du GJ, Qi LW, Calway T, He TC et al. Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells. Int J Oncol, 2013; 43(1): 289–296.
59. Hirata H, Hinoda Y, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Dahiya R. Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer, 2014; 110(6): 1645–1654.
60. Hirata H, Ueno K, Nakajima K, Tabatabai ZL, Hinoda Y, Ishii N, Dahiya R. Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br J Cancer, 2013; 108(10): 2070–2078.
61. Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S et al. Genistein up-regulates tumour suppressor microRNA-574-3p in prostate cancer. PLoS One, 2013; 8(3): e58929.
62. Bhatt P, Kumar V, Rastogi H, Malik MK, Dixit R, Garg S, et al. Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch. ACS Omega [Internet], 2023; 8(33): 30294–305. Available from: http://dx.doi.org/10.1021/acsomega.3c03158
63. Trejo-Solís C, Pedraza-Chaverrí J, Torres-Ramos M, Jiménez-Farfán D, Cruz Salgado A, Serrano-García N et al. Multiple molecular and cellular mechanisms of action of lycopene in cancer inhibition. Evid Based Complement Altern Med., 2013; 1–17. [DOI](https://doi.org/10.1155/2013/705121)
64. Uppala PT, Dissmore T, Lau BH, Andacht T, Rajaram S. Selective inhibition of cell proliferation by lycopene in MCF-7 breast cancer cells in vitro: a proteomic analysis. Phytother Res., 2013; 27(4): 595–601. [DOI](https://doi.org/10.1002/ptr.4764).
65. Gharib A, Faezizadeh Z. In vitro anti-telomerase activity of novel lycopene-loaded nanospheres in the human leukaemia cell line K562. Pharmacogn Mag., 2014; 10(Suppl 1): S157.
66. Haddad NF, Teodoro AJ, Leite de Oliveira F, Soares N, de Mattos RM, Hecht F et al. Lycopene and beta-carotene induce growth inhibition and proapoptotic effects on ACTH-secreting pituitary adenoma cells. PLoS One, 2013; 8(5): e62773.
67. Elgass S, Cooper A, Chopra M. Lycopene treatment of prostate cancer cell lines inhibits adhesion and migration properties of the cells. Int J Med Sci., 2014; 11(9): 948.
68. Holzapfel NP, Holzapfel BM, Champ S, Feldthusen J, Clements J, Hutmacher DW. The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence. Int J Mol Sci., 2013; 14(7): 14620–14646. [DOI](https://doi.org/10.3390/ijms140714620)
69. Yang CM, Yen YT, Huang CS, Hu ML. Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice. Mol Nutr Food Res., 2011; 55(4): 606–612.
70. Chari RV, Miller ML, Widdison WC. Antibody–drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed., 2014; 53(15): 3796–3827. [CAS](https://pubmed.ncbi.nlm.nih.gov/24610638/)
71. Pankaj. Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy. J Pharm Res Int [Internet], 2021; 54–63. Available from:

http://dx.doi.org/10.9734/jpri/2020/v32i3931024
72. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumours: improvement of tumour uptake, lowering of systemic toxicity, and distinct tumour imaging in vivo. Adv Drug Deliv Rev., 2013; 65(1): 71–79.
73. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumour blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev., 2011; 63(3): 136–151.
74. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev., 2014; 66: 2–25.
75. Patel NR, Pattni BS, Abouzeid AH, Torchilin VP. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev., 2013; 65(13–14): 1748–1762.
76. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urologic Oncology: Seminars and Original Investigations, 2008; 26(1): 74–85. [DOI](https://doi.org/10.1016/j.urolonc.2007.03.017)
77. Liang Y, Li Y, Wang H, Zhou J, Wang J, Regier T, Dai H. Co3O4 nanocrystals on graphene as a synergistic catalyst for oxygen reduction reaction. Nat Mater, 2011; 10(10): 780–786.
78. Bhatt P, Kumar V, Subramaniyan V, Nagarajan K, Sekar M, Chinni SV, et al. Plasma modification techniques for natural polymer-based drug delivery systems. Pharmaceutics [Internet], 2023; 15(8): 2066. Available from: http://dx.doi.org/10.3390/pharmaceutics15082066
79. Malik MK, Kumar V, Singh J, Bhatt P, Dixit R, Kumar S. Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility. ACS Omega [Internet], 2023; 8(13): 11750–67. Available from: http://dx.doi.org/10.1021/acsomega.2c05783
80. Kaurav M, Kanoujia J, Gupta M, Goyal P, Pant S, Rai S, et al. In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin. Phytomed Plus [Internet], 2023; 3(2): 100445. Available from: http://dx.doi.org/10.1016/j.phyplu.2023.100445
81. Goyal C, Bhatt P, Rawat S, Kumar Sharma V, Rani Ahuja M. Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents. Res J Pharm Technol [Internet], 2022; 5078–83. Available from: http://dx.doi.org/10.52711/0974-360x.2022.00853
82. Ahamed S, Bhatt P, Sultanuddin SJ, Walia R, Haque MA, InayathAhamed SB. An Intelligent IoT enabled Health Care Surveillance using Machine Learning. In: 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
83. Bhatt P, Kumar A, Shukla R. Nanorobots recent and future advances in cancer or dentistry therapy- A review. Am J PharmTech Res [Internet], 2019; 9(3): 321–31. Available from: http://dx.doi.org/10.46624/ajptr.2019.v9.i3.027
84. Sharma SK, Singh S. Antimicrobial herbal soap formulation. J Pharm Res Int [Internet], 2020; 82–8. Available from: http://dx.doi.org/10.9734/jpri/2020/v32i3630995
85. Sharma SK, Bhatt P, Asdaq SMB, Alshammari MK, Alanazi A, Alrasheedi NS, et al. Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review. J Infect Public Health [Internet], 2022; 15(5): 566–72. Available from: http://dx.doi.org/10.1016/j.jiph.2022.03.014
86. Singh S, Pankaj B, Nagarajan K, P. Singh N, Bala V. Blockchain with cloud for handling healthcare data: A privacy-friendly platform. Mater Today [Internet], 2022; 62: 5021–6. Available from: http://dx.doi.org/10.1016/j.matpr.2022.04.910
87. Malik MK, Bhatt P, Kumar T, Singh J, Kumar V, Faruk A, et al. Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices. Nat Prod J [Internet], 2022; 12. Available from: http://dx.doi.org/10.2174/2210315512666220819112334
88. Singh S, Kumar Sharma S, Mehrotra P, Bhatt P, Kaurav M. Blockchain technology for efficient data management in healthcare system: Opportunity, challenges and future perspectives. Mater Today [Internet], 2022; 62: 5042–6. Available from: http://dx.doi.org/10.1016/j.matpr.2022.04.998.
89. Malik MK, Bhatt P, Singh J, Kaushik RD, Sharma G, Kumar V. Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice. ACS Omega [Internet], 2022; 7(40): 35506–14. Available from: http://dx.doi.org/10.1021/acsomega.2c01309
90. Kaur T, Singh S. Controlled release of bi-layered malvidin tablets using 3D printing techniques. J Pharm Res Int [Internet], 2021; 70–8. Available from: http://dx.doi.org/10.9734/jpri/2020/v32i4031034
91. Bhatt P, Singh S, Sharma SK, Kumar V. Blockchain technology applications for improving quality of electronic healthcare system. In: Blockchain for Healthcare Systems. Boca Raton: CRC Press, 2021; 97–113.
92. Singh S, Bhatt P, Sharma SK, Rabiu S. Digital Transformation in Healthcare: Innovation and Technologies. In: Blockchain for Healthcare Systems. Boca Raton: CRC Press, 2021; 61–79.
93. Malik MK, Kumar V, Singh J, Bhatt P, Dixit R, Kumar S. Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility. ACS Omega [Internet], 2023; 8(13): 11750–67. Available from:

http://dx.doi.org/10.1021/acsomega.2c05783
94. Bhatt P, Kumar A, Shukla R. Nanorobots recent and future advances in cancer or dentistry therapy- A review. Am J PharmTech Res [Internet], 2019; 9(3): 321–31. Available from: http://dx.doi.org /10.46624/ajptr.2019.v9.i3.027
95. Sharma SK, Bhatt P. Controlled release of bi-layered EGCG tablets using 3D printing techniques. J Pharm Res Int [Internet], 2021; 5–13. Available from: http://dx.doi.org/10.9734/jpri/2020/v32i3931019
96. Kumar A, Bhatt P, Mishra N. Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review. J Chem Pharm Sci [Internet], 2019; 12(03): 71–8. Available from: http://dx.doi.org/10.30558/jchps.20191203002.
97. Baskar C, Ramakrishna S, Daniela La Rosa A, editors. Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
98. Bhatt P, Singh S, Kumar V, Nagarajan K, Mishra SK, Kumar Dixit P, et al. Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery. The Chinese Journal of Artificial Intelligence [Internet], 2023; 02. Available from: http://dx.doi.org/10.2174/012950375225081323112409294 6
99. Sahu KK, Kaurav M, Bhatt P, Minz S, Pradhan M, Khan J, et al. Utility of nanomaterials in wound management. In: Nanotechnological Aspects for Next-Generation Wound Management. Elsevier, 2024; 101–30.
100. Sharma SK, Singh L, Singh S. Comparative study between penicillin and ampicillin. Scholars Journal of Applied Medical Sciences, 2013; 1(4): 291-4.
101. Singh S, Thomas MB, Singh SP, Bhowmik D. Plants used in hepatoprotective remedies in traditional Indian medicine. Indian Journal of Research in Pharmacy and Biotechnology, 2013 Jan 1; 1(1): 58.
102. Thomas MB, Singh S. Review article on antimicrobial resistance. Indian Journal of Research in Pharmacy and Biotechnology, 2013 Mar 1; 1(2): 223.